Why the study?
Does Tc-99m tetrofosmin myocardial perfusion SPECT detect myocardial perfusion defects in patients with systemic lupus erythematosus?
Does Tc-99m tetrofosmin myocardial perfusion SPECT detect myocardial perfusion defects in patients with systemic lupus erythematosus?
Tc-99m tetrofosmin myocardial perfusion SPECT frequently detects subclinical myocardial perfusion defects in SLE patients, even in the absence of cardiac symptoms.
Suggests high subclinical ischemia burden in SLE; leaves open whether SPECT detection improves outcomes or warrants screening.
The purpose of this study was to evaluate the utility of single-photon emission computed tomography (SPECT) of technetium-99m tetrofosmin (Tc-99m TF) myocardial perfusion imaging to detect myocardial involvement in patients with systemic lupus erythematosus (SLE). Three groups of subjects-group 1: 25 SLE female patients with non-specific cardiac symptoms and signs, group 2: 25 female SLE patients without any cardiac symptoms and signs, and group 3: 25 female healthy controls-were evaluated by comparing rest and dipyridamole-stress Tc-99m TF myocardial perfusion SPECT. Tc-99m TF myocardial perfusion SPECT revealed perfusion defects in 88% and 40% of the cases in groups 1 and 2. respectively. However, no cases in group 3 demonstrated myocardial perfusion defects. Tc-99m TF myocardial perfusion SPECT is a useful noninvasive imaging modality to detect cardiac involvement in SLE patients with or without cardiac symptoms and signs.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2003) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: